Revenue from Operations

S.No. Particulars 2017 2018 2019 2020

1 Laurus Labs 1,892 2,027 2,236 2,797
2 Eris Lifesciences Ltd. 750 856 982 1,074
3 Ajanta Pharma Ltd 1,983 2,126 2,055 2,588

Reference https://www.screener.in/company/LAURUSLABS/
2021 CAGR
4,769 20%
1,212 10%
2,890 8%
`
Liquidity Test

S.No. Particulars Current Ratio Quick Ratio Cash Ratio

1 Laurus Labs 2.11 1.09 0.03
2 Eris Lifesciences Ltd. 1.67 0.30 0.18
3 Ajanta Pharma Ltd 2.71 1.62 0.30

Note-1
(in crores)
Cash & Bank Equivalents 39
Current Assets 3,164
Quick Assets 1630
Current Liabilities 1,502

Note-2
(in crores)
Cash & Bank Equivalents 38
Current Assets 636
Quick Assets 542
Current Liabilities 1785

Note-3
(in crores)
Cash & Bank Equivalents 210
Current Assets 1,904
Quick Assets 1,138
Current Liabilities 702
Note-1
Note-2
Note-3
Solvency Test

S.No. Particulars Debt Equity Total Assets to Debt

1 Laurus Labs 0.52 3.99
2 Eris Lifesciences Ltd. 0.00 N/A
3 Ajanta Pharma Ltd 0.01 120.29

Note-1
(in crores)
Debt 1411
Equity 2712
Total Assets 5625

Note-2
(in crores)
Debt 0
Equity 1577
Total Assets 1785

Note-3
(in crores)
Debt 31
Equity 2995
Total Assets 3729
Profitability Ratios

S.No. Particulars Gross Profit Margin

1 Laurus Labs 45%
2 Eris Lifesciences Ltd. 79%
3 Ajanta Pharma Ltd 72%

Note-1

Revenue from operations 4769

Less: Cost of Goods sold 2623
Gross Profit 2146

Less: Employee Benefit Expenses 402

Other Expenses 370
Depreciation and Ammortization 197
Operating Profit 1177

add:other income 26
less: finance cost 66
tax paid 51
Net profit 1086

Total Assets 5625

Note-2

Revenue from operations 1212

Less: Cost of Goods sold 250
Gross Profit 962

Less: Employee Benefit Expenses 231

Other Expenses 303
Depreciation and Ammortization 43
Operating Profit 385

add:other income 9
less: finance cost 2
tax paid 39
Net profit 353

Total Assets 1785

Note-3

Revenue from operations 2890

Less: Cost of Goods sold 809
Gross Profit 2081
Less: Employee Benefit Expenses 549
Other Expenses 520
Depreciation and Ammortization 116
Operating Profit 896

add:other income 24
less: finance cost 8
tax paid 243
Net profit 669

Total Assets 3729

Operating Profit Margin Net Profit Margin Return On Asset
25% 23% 19.31% Refer Note-1
32% 29% 20% Refer Note-2
31% 23% 18% Refer Note-3
Effeciency Ratio

S.No. Particulars Inventory Turnover Ratio

1 Laurus Labs 2.16
2 Eris Lifesciences Ltd. 2.98
3 Ajanta Pharma Ltd 1.28

Note-1
Cost of Goods sold 2623
Average Inventory 1214

Revenue from Operations/ Credit Sales 4769

Average Accounts Receivable 1029

Net Sales 4769

Total Assets 5625

Note-2
Cost of Goods sold 250
Average Inventory 84

Revenue from Operations/ Credit Sales 1,212

Average Accounts Receivable 149

Net Sales 1212

Total Assets 1785

Note-3
Cost of Goods sold 809
Average Inventory 631

Revenue from Operations/ Credit Sales 2,890

Average Accounts Receivable 757

Net Sales 2890

Total Assets 3729
Debtors Turnover Ratio Total Assets Turnover Average Collection Period Inventory days
4.63 0.85 78.76 168.93
8.13 0.68 44.87 122.64
3.82 0.78 95.61 284.69
Break-even point of Sales
Profit after Tax

S.No. Particulars 2017 2018 2019 2020

1 Laurus Labs 200 173 95 267
2 Eris Lifesciences Ltd. 247 294 291 296
3 Ajanta Pharma Ltd 507 469 387 468

Reference https://www.screener.in/company/LAURUSLABS/consolidated/#balance-sheet
2021 CAGR
1086 40%
353 7%
669 6%
Capital Expenditure in Last Year
Exceptional Items in Foot Note

Items of OCI
Specific News in 6 months
Laurus Labs joins hands with Unitaid, CHAI to develop and commercialise pediatric HIV drug combo
Laurus Labs signs an agreement with ..MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 a
Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release

Reference:
https://www.moneycontrol.com/news/business/stocks/
https://www.lauruslabs.com/media
piravir, oral COVID-19 antiviral medication
romoter, are set to release the pledge of shares of the company
Market Capitalization of Laurus Labs

Market Cap. As on 31/12/2021- 25,525 Cr.

CMP- 475

Trend in share price

Month Price
Jan-21 345
Feb-21 350 Price
Mar-21 360
800
Apr-21 458
May-21 523 700 679
649
Jun-21 679 600 605
Jul-21 605 523
500
Aug-21 649 458
Sep-21 599 400 350
345 360
Oct-21 515 300
Nov-21 502
200
Dec-21 538
100

0
Jan-21 Mar-21 May-21 Jul-21 Sep
 Price

679
649
605 599
523 515 538
502

ay-21 Jul-21 Sep-21 Nov-21

Growth in EPS of last 5 years
Year EPS
Mar-17 3.78
Mar-18 3.27
Mar-19 1.78
Mar-20 5
Mar-21 17.82

Difference between EPS and Diluted EPS?

Earnings per share (EPS) take into account only common shares, while diluted EPS includes convertible securities.
Dilutive effects occur when the number of shares increases—for example, through a new issue.
Generally, if a company has convertible securities, then the diluted EPS is less than its basic EPS.
rtible securities.